M08.0 M08.2 M08.3 M08.4 M08.8
Conditions
Interventions
Group 1: At the clinical visit t1/t1', the study group is divided into two groups with a stratified randomization. Arm 1 receives an individual sports advice and recommendation based on the results of
Sponsors
Professur für Biomechanik im Sport, Fakultät für Sport- und Gesundheitswissenschaften, Technische Universität München
Eligibility
Sex/Gender
All
Age
6 Years to 16 Years
Inclusion criteria
Inclusion criteria: T0: • Diagnosis of a JIA according to ILAR criteria (Petty et al., 2004) • new disease (shorter than 12 months) • Pre-treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and cortisone (maximum 0.2 mg / kg body weight prednisolone equivalent) is possible • Active JIA disease according to Wallace et al., 2004 • Age from 6 to 16 years • Involvement of the lower and / or upper limb and / or the spine • German Speaking T1': • Diagnosis of a JIA according to ILAR criteria (Petty et al., 2004), inactive state of disease (cJADAS 10: oligo =1.5, polyartikulär =2.5) • duration of disease at first visit to a pediatric rheumatoligist = 12 months, 6-months intervals of rheumatological screenings after first diagnosis, total duration of disease = 24 months at t1' • Pre-treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) and cortisone (maximum 0.2 mg / kg body weight prednisolone equivalent) is possible • Age from 6 to 17years • Involvement of the lower and / or upper limb and / or the spine • German Speaking
Exclusion criteria
Exclusion criteria: T0: • Pre-treatment with Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) > 3 months and Biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) > 3 months • Chronic pain disorder • Neurological diseases • abnormalities of cognitive function • No interest • Pretreatment with cortisone> 0.2 mg / kg body weight prednisolone equivalent • Participation in other interventional studies T1': • Already participating at t0 • Pre-treatment with Conventional Disease Modifying Anti-Rheumatic Drugs (cDMARDs) > 15 months and Biological Disease Modifying Anti-Rheumatic Drugs (bDMARDs) > 15 months • intra-articular injection ( 0.2 mg / kg • Participation in other interventional studies
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint in this study is the functional improvement of JIA patients with a functional deficit through an optimal sports recommendation. The parameters are collected at the measurement t1/t1' and t2. Changes are quantified with a fitness test (Deutscher Motorik-Test). | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint is a consistent minimal inflammatory activity and pain intensity as well as an improvement in health-related quality of life. The parameters are recorded at t1/t1' and t2 in the clinic. For this purpose, clinical parameters and subjective parameters of a patient survey are used. | — |
Countries
Germany
Contacts
Public ContactMatthias Hartmann
Deutsches Zentrum für Kinder- und Jugendrheumatologie
Outcome results
None listed